Earnings Release Sparks Whipsaw Trading on Exelixis Stock

The drug concern cited strong sales of its cancer drug Cabometyx for the earnings beat

Digital Content Manager
Feb 13, 2019 at 10:29 AM
facebook twitter linkedin

The shares of Exelixis Inc. (NASDAQ:EXEL) shot higher out of the gate this morning, but were last seen down 0.7% at $21.53, even though the company reported fourth-quarter earnings and revenue that beat analysts' forecasts. The biopharmaceutical company cited strong sales of its cancer drug Cabometyx for the better-than-expected results. 

EXEL stock remains down roughly 25% year-over-year, though it's recovered some since bottoming near $14 back in late October. The security is up almost 10% this year already, with recent support from its 60-day moving average helping along the way. 

Meanwhile, six out of eight analysts call the stock a "buy" or better. However, RBC just cut its price target to $34 from $35, and Oppenheimer lowered its price target to $31 from $40. Overall, the consensus 12-month price target stands at $28.44. 

The majority of options traders have been bullish on the stock, too. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), EXEL has a 10-day call/put ratio of 10.17 that sits in the 61st percentile of its annual range. This means that 10 calls have been purchased for every one put, and at a moderately faster pace than what is typically seen. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners